Future directions in chimeric antigen receptor T cell therapy.
Curr Opin Pediatr
; 29(1): 27-33, 2017 02.
Article
em En
| MEDLINE
| ID: mdl-27841776
ABSTRACT
PURPOSE OF REVIEW The impact of immunotherapy has grown exponentially in the past 5 years. Principle illustrations are encouraging results with engineered T cells expressing a chimeric antigen receptor (CAR). This experimental therapy is developing simultaneously in pediatric and adult clinical trials, making this field particularly relevant and exciting for pediatric oncologists. RECENT FINDINGS:
CAR-modified T cells targeting CD19 have produced dramatic antitumor responses in patients with relapsed/refractory B cell acute lymphoblastic leukemia. Clinical trials from several institutions, in both children and adults, using distinct CAR T cell products have demonstrated similar high complete remission rates of 61-93%, with durable remissions observed. Although the development of CARs for other malignancies has lagged behind, research into novel approaches to overcome inherent challenges is promising.SUMMARY:
Clinical trials of CAR-modified T cells have produced unprecedented results and are anticipated to have a broader impact as this approach expands into other indications, including other cancers and frontline therapy. The potential for long-term disease control, if fully realized, will have a transformative impact on the field.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos de Linfócitos T
/
Linfócitos T
/
Biomarcadores Tumorais
/
Antígenos CD19
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Terapia Baseada em Transplante de Células e Tecidos
/
Imunoterapia
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article